Trial Profile

A Phase I Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MB CART19.1 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man
Acronyms MB-CART19.1 r/r CD19+ BCM
Sponsors Miltenyi Biotec GmbH

Most Recent Events

24 Nov 2025 Phase is changed from phase 1/2 to phase 1. Primary end-points and treatments section are updated to remove respective phase 2 parts.
20 Aug 2025 Status changed from recruiting to active, no longer recruiting.
09 May 2025 Planned End Date changed from 1 Dec 2024 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com